Japan’s MHLW Reviews GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps Indication
The Ministry of Health, Labour and Welfare (MHLW) in Japan has begun the review process...
Company
Eli Lilly’s Verzenios Receives NMPA Approval for Extended Indication in Early-Stage Breast Cancer
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has announced that the National Medical...
Shanghai Biotech Cataya Secures $35 Million in Series B Financing for Synthetic Biology
Shanghai-based biotech company Cataya, which specializes in synthetic biology, has reportedly raised RMB 250 million...
Shanghai Junshi Biosciences’ JS207 Bispecific Antibody Receives NMPA Clinical Trial Approval
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...
United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...
Zai Lab’s Margenza (Margetuximab) Approved by China’s NMPA for HER2-Positive Breast Cancer
The National Medical Products Administration (NMPA) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB,...
MicuRx Pharmaceuticals Initiates Phase III Trial for MRX-4 in Complex Skin Infections
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...
EOC Pharma Group and Nanopeptide Biotechnology Forge Partnership for siRNA Drug Development
China-based EOC Pharma Group has announced a strategic partnership with fellow country siRNA firm, Nanopeptide...
Rapid Medical’s Tigertriever Receives Chinese Approval as Adjustable Thrombectomy Device
Israel-based medical device company Rapid Medical has announced that its revascularization device, Tigertriever, has received...
Genexine’s Eftansomatropin Alfa Achieves Phase III Endpoints in Growth Hormone Deficiency Trial
South Korea-based Genexine (KOSDAQ: 095700) has announced that its long-acting growth hormone product candidate, eftansomatropin...
Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2...
Innovac Therapeutics Secures $18 Million in Pre-Series A Financing for mRNA Vaccine Development
Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series...
AstraZeneca’s Soliris Gains Approval for Pediatric Generalized Myasthenia Gravis in Japan
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received an...
AstraZeneca and Daiichi Sankyo’s Enhertu Earns Two BTDs for HER2+ Malignancies
The US Food and Drug Administration (FDA) has granted AstraZeneca (AZ; NASDAQ: AZN) and Daiichi...
Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion
Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...
EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted...
Shandong Buchang Pharmaceuticals’ BC001 for mCRC Accepted for Review by NMPA
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced that the...
Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been...
Servier Group’s Pancreatic Cancer Therapy Onivyde Launches in Major Chinese Cities
France-based Servier has announced the first prescriptions for its pancreatic cancer therapy, Onivyde (irinotecan), in...